CLINICAL STUDIES
n-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study
Odd Johansen, MD*,
Magne Brekke, MD ,
Ingebjørg Seljeflot, PhD ,
Michael Abdelnoor, MPH, PhD and
Harald Arnesen, MD, PhD*
* Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
Cardiovascular Radiology, Ullevaal University Hospital, Oslo, Norway
Research Forum, Ullevaal University Hospital, Oslo, Norway
Manuscript received July 14, 1998;
revised manuscript received November 10, 1998,
accepted January 20, 1999.
Reprint requests and correspondence: Dr. Odd Johansen, Department of Cardiology, Ullevaal University Hospital, N-0407 OSLO, Norway
odd.johansen{at}ioks.uio.no
OBJECTIVES
The aim of the study was to investigate whether omega-3 fatty acids (n-3 FA) reduce the occurrence of restenosis after percutaneous transluminal coronary angioplasty.
BACKGROUND
Meta-analyses have shown significant reduction of restenosis after coronary angioplasty upon supplementation with n-3 FA.
METHODS
In a prospective, placebo-controlled, double-blind study, 500 patients were randomly allocated to treatment with n-3 FA (OmacorTM, Pronova AS, Oslo, Norway) 5.1 g/day or corn oil (placebo) starting at least two weeks prior to elective coronary angioplasty. The treatment was continued until restenosis evaluation by quantitative coronary angiography after six months. Stenosis was defined as a minimal luminal diameter (MLD) <40% of the reference diameter. Successful coronary angioplasty was defined as  20% acute gain in MLD and a residual stenosis <50%. Restenosis was defined as 20% late loss of diameter and stenosis >50% or an increase in stenosis of 0.7 mm. Three-hundred ninety-two patients fulfilled the criteria for initial stenosis and successful coronary angioplasty, and, except four patients who died, none were lost for follow-up.
RESULTS
Restenosis occurred in 108/266 (40.6%) of the treated stenoses in the Omacor group and in 93/263 (35.4%) in the placebo group (odds ratio [OR] 1.25, 95% confidence interval [CI] [0.87–1.80] p = 0.21). In the Omacor group one or more restenoses occurred in 90/196 (45.9%) patients as compared with 86/192 (44.8%) in the placebo group (OR 1.05, 95% CI [0.69–1.59] p = 0.82).
CONCLUSIONS
Supplementation with 5.1 g n-3 FA/day for six months, initiated at least two weeks prior to coronary angioplasty did not reduce the incidence of restenosis.
|
Abbreviations and Acronyms
| | CI | = confidence interval | | CART | = Coronary Angioplasty Restenosis Trial | | DHA | = docosahexaenoic acid | | EPA | = eicosapentaenoic acid | | EMPAR | = Enoxaparin MaxEPA Prevention of Angioplasty Restenosis | | MLD | = minimal luminal diameter | | NYHA | = New York Heart Association | | OR | = odds ratio | | n-3 FA | = omega-3 fatty acids |
|
This article has been cited by other articles:
|
|
|
|
 
I. Mangat
Do vegetarians have to eat fish for optimal cardiovascular protection?
Am. J. Clinical Nutrition,
May 1, 2009;
89(5):
1597S - 1601S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. CHAN and L. CHO
What can we expect from omega-3 fatty acids?
Cleveland Clinic Journal of Medicine,
April 1, 2009;
76(4):
245 - 251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J.A. Jenkins, A. R. Josse, P. Dorian, M. L. Burr, R. LaBelle Trangmar, C. W.C. Kendall, and S. C. Cunnane
Heterogeneity in Randomized Controlled Trials of Long Chain (Fish) Omega-3 Fatty Acids in Restenosis, Secondary Prevention and Ventricular Arrhythmias
J. Am. Coll. Nutr.,
June 1, 2008;
27(3):
367 - 378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Mozaffarian and E. B. Rimm
Fish intake, contaminants, and human health: evaluating the risks and the benefits.
JAMA,
October 18, 2006;
296(15):
1885 - 1899.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Lee, K. M. Gura, S. Kim, D. A. Arsenault, B. R. Bistrian, and M. Puder
Current Clinical Applications of {Omega}-6 and {Omega}-3 Fatty Acids
Nutr Clin Pract,
August 1, 2006;
21(4):
323 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L Breslow
n-3 Fatty acids and cardiovascular disease
Am. J. Clinical Nutrition,
June 1, 2006;
83(6):
S1477 - 1482S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H.K. Vogel, S. F. Bolling, R. B. Costello, E. M. Guarneri, M. W. Krucoff, J. C. Longhurst, B. Olshansky, K. R. Pelletier, C. M. Tracy, R. A. Vogel, et al.
Integrating Complementary Medicine Into Cardiovascular Medicine: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine)
J. Am. Coll. Cardiol.,
July 5, 2005;
46(1):
184 - 221.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T Erkkila, A. H Lichtenstein, D. Mozaffarian, and D. M Herrington
Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease
Am. J. Clinical Nutrition,
September 1, 2004;
80(3):
626 - 632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Kris-Etherton, W. S. Harris, L. J. Appel, and for the Nutrition Committee
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Arterioscler Thromb Vasc Biol,
February 1, 2003;
23(2):
e20 - 30.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Kris-Etherton, W. S. Harris, L. J. Appel, and for the Nutrition Committee
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Circulation,
November 19, 2002;
106(21):
2747 - 2757.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T Holm, A.K Andreassen, P Aukrust, K Andersen, O.R Geiran, J Kjekshus, S Simonsen, and L Gullestad
Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients
Eur. Heart J.,
March 1, 2001;
22(5):
428 - 436.
[Abstract]
[PDF]
|
|
|
|
|
|
|
O. Johansen, I. Seljeflot, A. T. Hostmark, and H. Arnesen
The Effect of Supplementation With Omega-3 Fatty Acids on Soluble Markers of Endothelial Function in Patients With Coronary Heart Disease
Arterioscler Thromb Vasc Biol,
July 1, 1999;
19(7):
1681 - 1686.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
